Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX Study)

Cancer Investigation

Volumn 24, Issue 2, 2006, Pages 154-159

  Hebbar, Mohamed ^a   Tournigand, Christophe ^b   Lledo, Gérard ^c   Mabro, May ^d   André, Thierry ^e   Louvet, Christophe ^b   Aparicio, Thomas ^f   Flesch, Michel ^g   Varette, Charles ^h   De Gramont, Aimery ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Clinique Saint Jean   (France)

^d FOCH HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f BICHAT HOSPITAL   (France)

^g Drevon Clinic   (France)

^h INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

Author keywords

Colorectal cancer; Irinotecan; Neurotoxicity; Oxaliplatin

Indexed keywords

CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; ONDANSETRON; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33644993432     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500524397     Document Type: Article

References (34)

1. Braun, A.H.; Achterrath, W.; Wilke, H.; Vanhoefer, U.; Harstrick, A.; Preusser, P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004, 100 (8), 1558-1577.
2. Saltz, L.B.; Cox, J.V.; Blanke, C.; Rosen, L.S.; Fehrenbacher, L.; et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000, 343 (13), 905-914.
3. Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004, 22 (1), 23-30.
4. de Gramont, A.; Bosset, J.F.; Milan, C.; Rougier, P.; Bouché, O.; et al. Randomized trial comparing monthly low-dose LV and fluorouracil bolus with bimonthly high-dose LV and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997, 15 (2), 808-815.
5. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18 (16), 2938-2947.
6. Andre, T.; Bensmaine, M.A.; Louvet, C.; Francois, E.; Lucas, V.; et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999, 17 (11), 3560-3568.
7. de Gramont, A.; Vignoud, J.; Tournigand, C.; Louvet, C.; André, T.; et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997, 33 (2), 214-219.
8. Douillard, J.Y.; Cunningham, D.; Roth, A.D.; Navarro, M.; James, R.D.; et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355 (9212), 1041-1047.
9. André, T.; Louvet, C.; Maindrault-Goebel, F.; Couteau, C.; Mabro, M.; et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur. J. Cancer 1999, 35 (9), 1343-1347.
10. Tournigand, C.; André, T.; Achille, E.; Lledo, G.; Flesh, M.; et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22 (2) 229-237.
11. Cassidy, J.; Misset, J.L. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 2002, 29 (5), (Suppl 15), 11-20.
12. Miller, A.B.; Hoogstraten, B.; Staquet, M.; Winkler, A. Reporting results of cancer treatment. Cancer 1981, 47 (1), 207-214.
13. Caussanel, J.P.; Lévi, F.; Brienza, S.; Misset, J.L.; Itzhaki, M.; et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. 1990, 82 (12), 1046-1050.
14. Andre, T.; Bensmaine, M.A.; Louvet, C.; Francois, E.; Lucas, V.; et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999, 17 (11), 3560-3568.
15. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481.
16. Bleiberg, H.; Hendlisz, A. Advanced colorectal cancer treatment in Europe: what have we achieved? Anticancer Drugs 2002, 13 (5), 461-471.
17. Ryan, D.P.; Clark, J.W.; Kulke, M.H.; Fuchs, C.S.; Earle, C.C.; et al. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003, 21 (4), 505-511.
18. de Gramont, A.; Cervantes, A.; André, T.; Figer, A.; Lledo, G.; et al. Optimox study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2005, 22 (14s), Abstr. 3525.
19. Cascinu, S.; Catalano, V.; Cordella, L.; Labianca, R.; Giordani, P.; et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2002, 20 (16), 3478-3483.
20. Penz, M.; Kornek, G.V.; Raderer, M.; Ulrich-Pur, H.; Fiebiger, W.; et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann. Oncol. 2001, 12 (3), 421-422.
21. Gamelin, L.; Boisdron-Celle, M.; Delva, R.; Guerin-Meyer, V.; Ifrah, N.; et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 2004, 10 (12) (Part 1), 4055-4061.
22. Gamelin, E.; Gamelin, L.; Bossi, L.; Quasthoff, S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. 2002, 29 (5) (Suppl. 15), 21-33.
23. Wilson, R.H.; Lehky, T.; Thomas, R.R.; Quinn, M.G.; Floeter, M.K.; et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 2002, 20 (7), 1767-1774.
24. Maindrault-Goebel, F.; Louvet, C.; André, T.; Carola, E.; Lotz, J.P.; et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX-6). Eur. J. Cancer 1999, 35 (9), 1338-1342.
25. Maindrault-Goebel, F.; de Gramont, A.; Louvet, C.; André, T.; Carola, E.; et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX-7). Eur. J. Cancer 2001, 37 (8), 1000-1005.
26. Hsieh, R.K.; Chao, T.Y.; Chen, W.S.; Yang, T.S.; Chen, L.T.; et al. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Invest. 2004, 22 (2), 171-179.
27. Pitot, H.C.; Rowland, K.M.; Sargent, D.J.; Philip, P.A.; Mitchell, E.P.; et al. N9841: a randomized phase III equivalence trial of irinotecan versus oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced colorectal cancer previously treated with 5-FU. Proc. Am. Soc. Clin. Oncol. 2005, 22 (14s), Abstr. 3506.
28. Seymour, M.T.; for the UK NCRI Colorectal Clinical Studies Group. Fluorouracil, oxaliplatin and CPT-11, use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2005, 22 (14s), Abstr. 3518.
29. Rosati, G.; Tucci, A.; Rinaldi, A.; Colarusso, D.; Pizza, C.; et al. A phase 11 study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Oncology 2004, 66 (5), 371-378.
30. Becouarn, Y.; Gamelin, E.; Coudert, B.; Négrier, S.; Pierga, J.Y.; et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J. Clin. Oncol. 2001, 19 (22), 4195-4201.
31. Taieb, J.; Artru, P.; Paye, F.; Louvet, C.; Perez, N.; et al. Intensive chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J. Clin. Oncol. 2005, 23 (3), 502-509.
32. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350 (23), 2335-2342.
33. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351 (4), 337-345.
34. Iqbal, S.; Stoehlmacher, J.; Lenz, H.J. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest. 2004, 22 (5), 762-773.